Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2

Foster, Scott A.; Whalen, Daniel M.; Özen, Ayşegül; Wongchenko, Matthew J.; Yin, JianPing; Yen, Ivana; Schaefer, Gabriele; Mayfield, John D.; Chmielecki, Juliann; Stephens, Philip J.; Albacker, Lee A.; Yan, Yibing; Song, Kyung; Hatzivassiliou, Georgia; Eigenbrot, Charles; Yu, Christine; Shaw, Andrey S.; Manning, Gerard; Skelton, Nicholas J.; Hymowitz, Sarah G.; Malek, Shiva

doi:10.1016/j.ccell.2016.02.010

Title: Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2

Full Record
Other Related Research

Publication Date:: Fri Apr 01 00:00:00 EDT 2016

Sponsoring Org.:: USDOE

OSTI Identifier:: 1351014

Alternate Identifier(s):: OSTI ID: 1327933

Resource Type:: Published Article

Journal Name:: Cancer Cell

Additional Journal Information:: Journal Name: Cancer Cell Journal Volume: 29 Journal Issue: 4; Journal ID: ISSN 1535-6108

Publisher:: Elsevier

Country of Publication:: United States

Language:: English

Citation Formats


                    Foster, Scott A., Whalen, Daniel M., Özen, Ayşegül, Wongchenko, Matthew J., Yin, JianPing, Yen, Ivana, Schaefer, Gabriele, Mayfield, John D., Chmielecki, Juliann, Stephens, Philip J., Albacker, Lee A., Yan, Yibing, Song, Kyung, Hatzivassiliou, Georgia, Eigenbrot, Charles, Yu, Christine, Shaw, Andrey S., Manning, Gerard, Skelton, Nicholas J., Hymowitz, Sarah G., and Malek, Shiva. Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2.  United States: N. p., 2016. 
Web.  doi:10.1016/j.ccell.2016.02.010.

Copy to clipboard


                    Foster, Scott A., Whalen, Daniel M., Özen, Ayşegül, Wongchenko, Matthew J., Yin, JianPing, Yen, Ivana, Schaefer, Gabriele, Mayfield, John D., Chmielecki, Juliann, Stephens, Philip J., Albacker, Lee A., Yan, Yibing, Song, Kyung, Hatzivassiliou, Georgia, Eigenbrot, Charles, Yu, Christine, Shaw, Andrey S., Manning, Gerard, Skelton, Nicholas J., Hymowitz, Sarah G., & Malek, Shiva. Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2.  United States.  https://doi.org/10.1016/j.ccell.2016.02.010

Copy to clipboard


                    Foster, Scott A., Whalen, Daniel M., Özen, Ayşegül, Wongchenko, Matthew J., Yin, JianPing, Yen, Ivana, Schaefer, Gabriele, Mayfield, John D., Chmielecki, Juliann, Stephens, Philip J., Albacker, Lee A., Yan, Yibing, Song, Kyung, Hatzivassiliou, Georgia, Eigenbrot, Charles, Yu, Christine, Shaw, Andrey S., Manning, Gerard, Skelton, Nicholas J., Hymowitz, Sarah G., and Malek, Shiva. Fri .  
"Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2".  United States.  https://doi.org/10.1016/j.ccell.2016.02.010.

Copy to clipboard


                    
@article{osti_1351014,

  title        = {Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2},

  author       = {Foster, Scott A. and Whalen, Daniel M. and Özen, Ayşegül and Wongchenko, Matthew J. and Yin, JianPing and Yen, Ivana and Schaefer, Gabriele and Mayfield, John D. and Chmielecki, Juliann and Stephens, Philip J. and Albacker, Lee A. and Yan, Yibing and Song, Kyung and Hatzivassiliou, Georgia and Eigenbrot, Charles and Yu, Christine and Shaw, Andrey S. and Manning, Gerard and Skelton, Nicholas J. and Hymowitz, Sarah G. and Malek, Shiva},

  abstractNote = {},

  doi          = {10.1016/j.ccell.2016.02.010},

  journal      = {Cancer Cell},

  number       = 4,

  volume       = 29,

  place        = {United States},

  year         = {Fri Apr 01 00:00:00 EDT 2016},

  month        = {Fri Apr 01 00:00:00 EDT 2016}

}

Copy to clipboard

Journal Article:

Free Publicly Available Full Text

Publisher's Version of Record
https://doi.org/10.1016/j.ccell.2016.02.010

Other availability

Search WorldCat to find libraries that may hold this journal

Citation Metrics:

Cited by: 129 works

Citation information provided by
Web of Science

Save / Share:

Export Metadata

Save to My Library

Similar Records in DOE PAGES and OSTI.GOV collections:

Quantifying the effects of co-expressing EGFR and HER2 on HER activation and trafficking

Journal Article Shankaran, Harish ; Zhang, Yi ; Opresko, Lee ; ... - Biochemical and Biophysical Research Communications, 371(2):220-224

The integration of experimental measurements and computational predictions is a powerful means to understand the molecular mechanisms of complex biological systems. The human epidermal growth factor receptor (HER) system is an intricately regulated system that plays critical roles in development and tumorigenesis. Here, we apply integrated experimentation and modeling to analyze HER receptor activation in a panel of cell lines expressing different levels of HER1 and HER2. A mathematical model that includes the fundamental biochemical/biophysical processes involved in receptor activation was used to fit the experimental data, and 19 independent parameters including receptor dimerization affinities, trafficking rates and relative phosphorylationmore »« less
https://doi.org/10.1016/j.bbrc.2008.04.043
Model-based Analysis of HER Activation in Cells Co-Expressing EGFR, HER2 and HER3.

Journal Article Shankaran, Harish ; Zhang, Yi ; Tan, Yunbing ; ... - PLoS Computational Biology, 9(8):e1003201

The HER/ErbB family of receptor tyrosine kinases drive critical responses in normal physiology and cancer, and the expression levels of the various HER receptors are critical determinants of clinical outcomes. HER activation is driven by the formation of various dimer complexes between members of this receptor family. The HER dimer types can have differential effects on downstream signaling and phenotypic outcomes. We constructed an integrated mathematical model of HER activation and trafficking to quantitatively link receptor expression levels to dimerization and activation. We parameterized the model with a comprehensive set of HER phosphorylation and abundance data collected in a panelmore »« less
https://doi.org/10.1371/journal.pcbi.1003201
An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling

Journal Article Karoulia, Zoi ; Wu, Yang ; Ahmed, Tamer A. ; ... - Cancer Cell

The complex biochemical effects of RAF inhibitors account for both the effectiveness and mechanisms of resistance to these drugs, but a unified mechanistic model has been lacking. Here we show that RAF inhibitors exert their effects via two distinct allosteric mechanisms. Drug resistance due to dimerization is determined by the position of the αC helix stabilized by inhibitor, whereas inhibitor-induced RAF priming and dimerization are the result of inhibitor-induced formation of the RAF/RAS-GTP complex. The biochemical effect of RAF inhibitor in cells is the combined outcome of the two mechanisms. Therapeutic strategies including αC-helix-IN inhibitors are more effective in multiplemore »« less
Cited by 94
https://doi.org/10.1016/j.ccell.2016.06.024

Full Text Available
Oncogenic DIRAS3 promotes malignant phenotypes of glioma by activating EGFR-AKT signaling

Journal Article Peng, Yong ; Jia, Jiaoying ; Jiang, Zhongzhong ; ... - Biochemical and Biophysical Research Communications

Highlights: • DIRAS3 is up-regulated in gliomas, especially in Classical and Mesenchymal subtype GBMs. • DIRAS3 promotes proliferation and invasion of glioma cells. • DIRAS3 enhances EGFR-AKT signaling activation at the downstream of EGFR through increasing AKT phosphorylation. Epidermal growth factor receptor (EGFR)-Akt signaling cascade activation plays a pivotal role in gliomas malignant phenotype, especially in Classical and Mesenchymal subtype gliomas. However, the molecules and mechanisms underlying regulate and maintain the activation of EGFR-AKT signaling remains unclear. Previously reports showed that DIRAS3 inhibits cell proliferation and induces autophagy in ovarian, breast, lung and prostate cancers, which is heterozygosity loss ormore »« less
https://doi.org/10.1016/J.BBRC.2018.09.119
Inhibition of glycolysis by a novel EGFR/HER2 inhibitor KU004 suppresses the growth of HER2+ cancer

Journal Article Tian, Chongchong ; Yuan, Ziqiao ; Xu, Dengqiu ; ... - Experimental Cell Research

Upregulation of glycolysis was often observed in human HER2-overexpressing cancers. In this study, we demonstrated that KU004, a dual novel EGFR/HER2 inhibitor, disrupted cancer cell proliferation via modulation of glycolysis. KU004, inhibited the Warburg effect by suppressing hexokinase II (HK2) expression at the transcriptional and post-translational levels. Further study demonstrated that the downregulation of HKII by KU004 was mainly mediated by the PI3K/Akt signaling pathway. Furthermore, the role of HKII downregulation in KU004-mediated antitumor effect was also confirmed in our in vivo xenograft model. Collectively, these data suggest that multifaceted targeting the aberrant glucose metabolism along with the upstream HER2more »« less
https://doi.org/10.1016/J.YEXCR.2017.05.019

Similar Records